Abstract:
Described herein are α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.
Abstract:
Methods and apparatus for firing a projectile in response to a threat according to various aspects of the present invention operate in conjunction with a computer coupled to a launch system for the projectile. The computer may be configured to select the projectile from multiple available projectiles and calculate a fire control solution according to a characteristic of the selected projectile. Calculating the fire control solution may comprise deriving the fire control solution from a look-up table according to a predicted intercept point. The computer may initiate a launch of the selected projectile and provide the fire control solution to the selected projectile.
Abstract:
The present invention provides cysteine prodrugs for the treatment of schizophrenia and drug addiction. The invention further encompasses pharmaceutical compositions containing prodrugs and methods of using the prodrugs and compositions for treatment of schizophrenia and drug addiction.
Abstract:
An electronic pneumatic brake system for trains which significantly improves brake cylinder pressure build-up time and facilitates essentially instantaneous and simultaneous braking on all cars of the train. The electronic pneumatic brake system includes electronic pneumatic control valves on the cars which individually control the braking on each car or a pack of cars and which are regulated by an electronic pneumatic controller on each car that receives electronic braking and release signals by way of wireless communication from an electronic head end unit on the lead locomotive, or where no head end unit is provided in the locomotive, receives pneumatic braking signals through the brake pipe.
Abstract:
This application describes, in part, system and methods for reducing unintentional performance of actions, such as orders, on a computing device. In some implementations, ordering may be controlled by identifying an input within an action region and determining that the input is an intentional input before completing an order. For example, to be considered an intentional input, the input may need to remain in an action region for a predetermined time duration, or may need to move across a majority of the action region.
Abstract:
Some examples provide for content updates based on the state of content described at least partially in a markup language and caused to be displayed in a browser window. A web application causes the content to be displayed and tracks state changes of the content caused by user interactions with the displayed content. The web application causes the display of updates to the content that are received responsive to requests sent based on the user interactions. The web application can exclude from display those updates that are associated with an outdated state of the content.
Abstract:
A test device may include an application that accesses online content. In some examples, a test intermediary and/or a test user interface (UI) are downloaded to the test device in response to a request by the application for obtaining the content from a network location. The test intermediary may be positioned to receive communications between the application and the content during testing of the content and/or the application. For example, the test intermediary may intercept metrics and other callbacks passed between the content and the application during manual or automated testing. In some instances, the test intermediary may provide the metrics and/or other test outputs for display in the test user UI rendered on the test device. The content may be rendered to be functional within the test UI, and the existence of the test intermediary and/or the test UI may be transparent to the application and the content.
Abstract:
The present invention provides cysteine and cystine bioisosteres for the treatment of schizophrenia and drug addiction. The invention further encompasses pharmaceutical compositions containing such bioisosteres and methods of using the bioisosteres for treatment of schizophrenia and drug addiction.
Abstract:
Described herein are α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.
Abstract:
The present invention provides cysteine and cystine prodrugs for the treatment of schizophrenia and drug addiction. The invention further encompasses pharmaceutical compositions containing prodrugs and methods of using the prodrugs and compositions for treatment of schizophrenia and drug addiction.